EGFR and non-small cell lung carcinoma: The existing literature suggests that adverse events associated with brigatinib are typically manageable, the most common ones being increased creatine phosphokinase, diarrhea, and nausea [12], though there are limited data on the safety of brigatinib monotherapy in EGFR-mutated NSCLC.